Overview

A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents

Status:
Completed

Trial end date:
2009-12-01

Target enrollment:
0

Participant gender:
All

Summary

This study is designed to collect additional pharmacokinetic and safety data of voriconazole in immunocompromised adolescents receiving intravenous and oral voriconazole. This will help establish voriconazole dosing recommendations for adolescents.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Treatments:

Voriconazole

Criteria

Inclusion Criteria:

- Subjects who are expected to develop neutropenia following chemotherapy.

- Subjects who require treatment for the prevention of systemic fungal infection.

Exclusion Criteria:

- Subjects with a history of severe intolerance of azole antifungal agents.

- Subjects with documented bacterial or viral infection at the time of study entry who
are not responding to appropriate treatment against the infection.